Because of the unsatisfactory efficacy of ICI monotherapy, ICIs combined with chemotherapy, radiotherapy, or anti-angiogenesis therapy have been approved as successful first-line therapy for several malignant tumors regardless of the PD-L1 expression level in tumor tissues (4). This evidence concerns the gene CD274 and cancer.